MSB 7.69% $1.19 mesoblast limited

Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-20

  1. 12,393 Posts.
    lightbulb Created with Sketch. 3370
    That fits nicely with the H12023 approval period

    Mesoblast has comb through and answered all the CRL questions
    Got ODAC 9-1 vote
    Got long term data as insurance

    What else does the FDA need?
    Ryoncil approval will certainly change the dynamics of this company - we are on our way to commercialisation - finally!!!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.19
Change
0.085(7.69%)
Mkt cap ! $1.358B
Open High Low Value Volume
$1.10 $1.20 $1.09 $13.21M 11.37M

Buyers (Bids)

No. Vol. Price($)
1 15000 $1.19
 

Sellers (Offers)

Price($) Vol. No.
$1.19 75212 5
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.